New #JITC article: Association of metabolomics with PD-1 inhibitor plus chemotherapy outcomes in patients with advanced non-small-cell lung cancer bit.ly/4d4QzsH

New #JITC article: Tumor-targeted therapy with BRAF-inhibitor recruits activated dendritic cells to promote tumor immunity in melanoma bit.ly/3JmivuK David W. Mullins

New #JITC article: Tetracyclines enhance antitumor T-cell immunity via the Zap70 signaling pathway bit.ly/3xxrxSO

Meet the Author: Amin H. Nassar (Amin Nassar, MD), a medical oncology fellow from Yale Cancer Center, is co-1st author of “Clinical Outcomes and Safety of Immune Checkpoint Inhibitors in Patients with Solid Tumors and Paraneoplastic Syndromes,” recently published in #JITC ! 1/6

New #JITC article: Preclinical evaluation of two phylogenetically distant arenavirus vectors for the development of novel immunotherapeutic combination strategies for cancer treatment bit.ly/3Q6zPHK

Here’s a closer look at the recent #JITC article: “Respiratory Complex I Regulates Dendritic Cell Maturation in Explant Model of Human Tumor Immune Microenvironment” by Rita Turpin Juha Klefström Klefström Lab from University of Helsinki FCI Finnish Cancer Institute 1/10

New #JITC article: Phase 1a dose escalation study of ivonescimab (AK112/SMT112), an anti-PD-1/VEGF-A bispecific antibody, in patients with advanced solid tumors bit.ly/448qANa Sophia Frentzas

New #JITC article: Dysregulation of CD4+ and CD8+ resident memory T, myeloid, and stromal cells in steroid-experienced, checkpoint inhibitor colitis bit.ly/4488Q4k Arjun Arkal Rao KattahLab

New #JITC commentary: Immunotherapy-based regimens for patients with EGFR-mutated non-small cell lung cancer who progressed on EGFR-TKI therapy bit.ly/3xDnhl1

New #JITC article: Preclinical evaluation and first-in-dog clinical trials of PBMC-expanded natural killer cells for adoptive immunotherapy in dogs with cancer bit.ly/4cXZ09p Cordelia Dunai, Ph.D.

New #JITC short report: Spatial comparison of molecular features associated with resistance to pembrolizumab in BCG unresponsive bladder cancer bit.ly/3UkUNVL Noah Frydenlund Bonnie Choy, MD Joshua Meeks

New #JITC article: Combinational therapy of CAR T-cell and HDT/ASCT demonstrates impressive clinical efficacy and improved CAR T-cell behavior in relapsed/refractory large B-cell lymphoma bit.ly/4aD3rET

New #JITC article: Efficacy of LCMV-based cancer immunotherapies is unleashed by intratumoral injections of polyI:C bit.ly/49EVvBR Ignacio Melero

View the April edition of the #JITC Digest! Review cutting-edge articles on topics such as a cost-utility analysis on #TIL therapy. Check out a special feature interview with JITC's Incoming Editor-in-Chief Michael T. Lotze, MD.

View April Digest: sitcancer.org/blogs/jitc-pub…

Hot off the #JITC Press-Dr Robert Canter & team published research: Preclinical evaluation and first-in-dog clinical trials of PBMC-expanded natural killer cells for adoptive immunotherapy in dogs with cancer bit.ly/4cXZ09p
#cancerresearch #immunotherapy UC Davis Health

Regarding her publication in #JITC , she shared, “I am excited that we have the opportunity to present our work to an audience that is just as enthusiastic about cancer research as we are.” 4/5

He is proud to publish in #JITC because “JITC provides state-of-the-art research in the field of immunology. The review process is rigorous and well-structured.” 5/6

JITC | In a new study, researchers found that metformin activates the body's immune cells. This effect is particularly evident in dendritic cells, which most effectively help the immune system recognise cancer cells as foreign entities.
doi:10.1136/jitc-2023-008053

Journal for ImmunoTherapy of Cancer Noah Frydenlund Bonnie Choy, MD Joshua Meeks Intriguing study highlighted in #JITC . Spatial analysis provides critical insights into the resistance mechanisms, which is vital for improving therapeutic strategies. For a deeper dive into this research or similar topics, check out sciqst.com, where our advanced AI

New #JITC article: Oral PD-L1 inhibitor GS-4224 selectively engages PD-L1 high cells and elicits pharmacodynamic responses in patients with advanced solid tumors bit.ly/3PZFwaw